BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38601453)

  • 1. Oncogene alterations in non-small cell lung cancer with
    Kitai H; Ebi H
    Transl Lung Cancer Res; 2024 Mar; 13(3):684-688. PubMed ID: 38601453
    [No Abstract]   [Full Text] [Related]  

  • 2. Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
    Fumarola C; Bozza N; Castelli R; Ferlenghi F; Marseglia G; Lodola A; Bonelli M; La Monica S; Cretella D; Alfieri R; Minari R; Galetti M; Tiseo M; Ardizzoni A; Mor M; Petronini PG
    Front Oncol; 2019; 9():179. PubMed ID: 30972293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
    Addeo A; Rothschild SI; Holer L; Schneider M; Waibel C; Haefliger S; Mark M; Fernandez E; Mach N; Mauti L; Jermann PM; Alborelli I; Calgua B; Savic-Prince S; Joerger M; Früh M
    Lung Cancer; 2022 Oct; 172():154-159. PubMed ID: 36099710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
    Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
    Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
    Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
    Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
    Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.
    Elakad O; Lois AM; Schmitz K; Yao S; Hugo S; Lukat L; Hinterthaner M; Danner BC; von Hammerstein-Equord A; Reuter-Jessen K; Schildhaus HU; Ströbel P; Bohnenberger H
    Cancer Med; 2020 May; 9(10):3574-3583. PubMed ID: 32207251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
    Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
    Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
    Fumarola C; Cretella D; La Monica S; Bonelli MA; Alfieri R; Caffarra C; Quaini F; Madeddu D; Falco A; Cavazzoni A; Digiacomo G; Mazzaschi G; Vivo V; Barocelli E; Tiseo M; Petronini PG; Ardizzoni A
    Oncotarget; 2017 Nov; 8(54):91841-91859. PubMed ID: 29190880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
    Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
    Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
    Weiss J; Sos ML; Seidel D; Peifer M; Zander T; Heuckmann JM; Ullrich RT; Menon R; Maier S; Soltermann A; Moch H; Wagener P; Fischer F; Heynck S; Koker M; Schöttle J; Leenders F; Gabler F; Dabow I; Querings S; Heukamp LC; Balke-Want H; Ansén S; Rauh D; Baessmann I; Altmüller J; Wainer Z; Conron M; Wright G; Russell P; Solomon B; Brambilla E; Brambilla C; Lorimier P; Sollberg S; Brustugun OT; Engel-Riedel W; Ludwig C; Petersen I; Sänger J; Clement J; Groen H; Timens W; Sietsma H; Thunnissen E; Smit E; Heideman D; Cappuzzo F; Ligorio C; Damiani S; Hallek M; Beroukhim R; Pao W; Klebl B; Baumann M; Buettner R; Ernestus K; Stoelben E; Wolf J; Nürnberg P; Perner S; Thomas RK
    Sci Transl Med; 2010 Dec; 2(62):62ra93. PubMed ID: 21160078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer.
    Moes-Sosnowska J; Chorostowska-Wynimko J
    Front Oncol; 2022; 12():780650. PubMed ID: 35402233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Primary Drug Resistance in
    Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
    Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
    Lim SH; Sun JM; Choi YL; Kim HR; Ahn S; Lee JY; Lee SH; Ahn JS; Park K; Kim JH; Cho BC; Ahn MJ
    Cancer; 2016 Oct; 122(19):3024-31. PubMed ID: 27315356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
    Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
    Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.